Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：33

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[11] Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
Vazzana, C.
Morano, S.
Di Lascio, A.
Grana, C.
Chinol, M.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S880 - S880
[12] Radium-223 dichloride for the treatment of metastatic prostate cancer
Turner, Philip Geoffrey
O'Sullivan, Joe
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (14) : 2105 - 2111
[13] Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
Shore, Neal
Higano, Celestia S.
George, Daniel J.
Sternberg, Cora N.
Saad, Fred
Tombal, Bertrand
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Sartor, Oliver
PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (04) : 680 - 688
[14] Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
Neal Shore
Celestia S. Higano
Daniel J. George
Cora N. Sternberg
Fred Saad
Bertrand Tombal
Kurt Miller
Jan Kalinovsky
XiaoLong Jiao
Krishna Tangirala
Oliver Sartor
Prostate Cancer and Prostatic Diseases, 2020, 23 : 680 - 688
[15] Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience
Peters, Niamh
Gaffney, John
Connolly, Emma
Bambury, Richard
Power, Derek Gerard
Kelly, Paul J.
Jamaluddin, Muhammad Faisal
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[16] Outcomes with Radium-223 therapy in clinical practice of metastatic castration resistant prostate cancer (mCRPC).
Alva, Ajjai Shivaram
Nordquist, Luke T.
Daignault, Stephanie
George, Saby
Ramos, Jorge
Isharwal, Sudhir
McDonald, Matthew
Campbell, Gregory
Danchaivijitr, Pongwut
Albany, Costantine
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[17] A Phase lb Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Fong, Lawrence
Morris, Michael J.
Sartor, Oliver
Higano, Celestia S.
Pagliaro, Lance
Alva, Ajjai
Appleman, Leonard J.
Tan, Winston
Vaishampayan, Ulka
Porcu, Raphaelle
Tayama, Darren
Kadel, Edward E., III
Yuen, Kobe C.
Datye, Asim
Armstrong, Andrew J.
Petrylak, Daniel P.
CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4746 - 4756
[18] Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden
Stattin, Par
Westerberg, Marcus
Lissbrant, Ingela Franck
Eriksson, Marie Hjalm
Kjellman, Anders
Ullen, Anders
Vassilev, Zdravko
Sandstrom, Per
Weinrib, Rachel
Martinez, David
Garcia-Albeniz, Xabier
CLINICAL GENITOURINARY CANCER, 2023, 21 (01) : 107.e1 - 107.e9
[19] Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety
Nilsson, Sten
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (07) : 1127 - 1136
[20] Impact of treatment delay in Radium-223 Dichloride therapy of metastatic castration-resistant prostate cancer patients
Fosbol, M. O.
Holm, S.
Petersen, P. M.
Daugaard, G.
Mortensen, J.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S214

← 1 2 3 4 5 →